Neurogene (NGNE) Total Non-Current Liabilities (2013 - 2026)

Neurogene has reported Total Non-Current Liabilities for 12 years, with the latest figure at $25.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 8.11% year-over-year to $25.4 million; the trailing twelve-month figure through Mar 2026 stood at $25.4 million (up 8.11% YoY), and the FY2025 full-year result was $23.3 million, down 5.47% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $25.4 million, up from $23.3 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $35.5 million in Q4 2023, with the low at $10.6 million in Q4 2022.
• Historically, Total Non-Current Liabilities has averaged $23.9 million across 5 years, with a median of $24.0 million in 2025.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 234.11% — and 2024, when it slumped 30.68%.
• Neurogene's Total Non-Current Liabilities stood at $10.6 million in 2022, then jumped by 234.11% to $35.5 million in 2023, then sank by 30.68% to $24.6 million in 2024, then fell by 5.47% to $23.3 million in 2025, then advanced by 8.88% to $25.4 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $25.4 million (Q1 2026), $23.3 million (Q4 2025), and $22.2 million (Q3 2025), per Business Quant data.